Previous Article | Next Article ![]()
J. Virol., 06 1996, 3741-3752, Vol 70, No. 6
VM Hirsch, TR Fuerst, G Sutter, MW Carroll, LC Yang, S Goldstein, M Piatak Jr, WR Elkins, WG Alvord, DC Montefiori, B Moss and JD Lifson
The dynamics of plasma viremia were explored in a group of 12 simian
immunodeficiency virus (SIV)-infected rhesus macaques (Macaca mulatta) that
had received prior immunization with either nonrecombinant or trivalent
(gag-pol, env) SIV-recombinant vaccinia viruses. Three distinct patterns of
viral replication observed during and following primary viremia accounted
for significant differences in survival times. High-level primary plasma
viremia with subsequently increasing viremia was associated with rapid
progression to AIDS (n = 2). A high- level primary plasma virus load with a
transient decline and subsequent progressive increase in viremia in the
post-acute phase of infection was associated with progression to AIDS
within a year (n = 6). Low levels of primary plasma viremia followed by
sustained restriction of virus replication were associated with maintenance
of normal lymphocyte subsets and intact lymphoid architecture (n = 4),
reminiscent of the profile observed in human immunodeficiency virus type
1-infected long- term nonprogressors. Three of four macaques that showed
this pattern had been immunized with an SIV recombinant derived from the
attenuated vaccinia virus, modified vaccinia virus Ankara. These data link
the dynamics and extent of virus replication to disease course and suggest
that sustained suppression of virus promotes long-term, asymptomatic
survival of SIV-infected macaques. These findings also suggest that vaccine
modulation of host immunity may have profound beneficial effects on the
subsequent disease course, even if sterilizing immunity is not achieved.
Copyright © 1996, American Society for Microbiology
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20892, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|